Treatment intensification for patients with type 2 diabetes and poor glycaemic control

Diabetes, Obesity and Metabolism

Volumn 18, Issue 9, 2016, Pages 892-898

  Fu, A Z ^a   Sheehan, J J ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

database research; observational study

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG THERAPY; DRUG TREATMENT FAILURE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT INTENSIFICATION; UNITED STATES; VERY ELDERLY; ADOLESCENT; AGONISTS; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; KAPLAN MEIER METHOD; METABOLISM; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84983313723     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12683     Document Type: Article

References (19)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
2. Garber AJ, Abrahamson MJ, Barzilay JI et al. Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract 2015; 21: 438–447.
3. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327–336.
4. McCoy RG, Zhang Y, Herrin J et al. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. Am J Manag Care 2015; 21: e288–e296.
5. Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P. Does clinical inertia vary by personalized a1c goal? A study of predictors and prevalence of clinical inertia in a us managed care setting. Endocr Pract 2016; 22: 151–161.
6. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14: 100.
7. Hansen LG, Chang S. Health research data for the real world: the MarketScan databases, 2011. Available from URL: http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf. Accessed 20 November 2015.
8. National Quality Forum. Adding Value to Diabetes Quality Measures: Opportunities and Methodological Challenges. Washington, DC: National Quality Forum, 2015.
9. Young BA, Lin E, Von KM et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008; 14: 15–23.
10. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–619.
11. Phillips LS, Branch WT, Cook CB et al. Clinical inertia. Ann Intern Med 2001; 135: 825–834.
12. Raebel MA, Ellis JL, Schroeder EB et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Pharmacoepidemiol Drug Saf 2014; 23: 699–710.
13. Goldstein BJ, Gomis R, Lee HK, Leiter LA. Type 2 diabetes–treat early, treat intensively. Int J Clin Pract Suppl 2007; 157: 16–21.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
15. Freeman JS, Gross B. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review. Expert Rev Clin Pharmacol 2012; 5: 31–42.
16. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011; 13: 765–769.
17. Selby JV, Peng T, Karter AJ et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care 2004; 10: 163–170.
18. Romanelli RJ, Chung S, Pu J, Nimbal V, Zhao B, Palaniappan L. Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2015; 108: 170–178.
19. Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications 2014; 28: 831–835.